Promising results with Combat HIVEC in high risk non-muscle invasive bladder cancer patients
August 2020

Promising preliminary results from HIVEC-HR randomized trial with 24 months of median follow-up, presented by a group of urologists from the Hospital Universitario 12 de Octubre, Madrid, peaked great interest at AUA 2020, because of the growing need to find a valid alternative to BCG for patients with non-muscle invasive bladder cancer (NMIBC). 

Chemohyperthermia (CHT) with mitomycin C using the COMBAT BRS recirculation system in high risk NMIBC patients seems at least not to be inferior to BCG in terms of efficacy. Moreover, patients under CHT have milder side effects than those under BCG treatment.

Read more in The Journal of Urology: 
https://www.auajournals.org/doi/abs/10.1097/JU.0000000000000823.01#.Xo2qHxYSrtk.email

Back to main Go to news
This site uses cookies to improve your user experience. You may find out more about in our Privacy Policy. By using this website you accept our use of cookies.
OK